evidencegaps
Studies

Primary studies

26,293 studies included by 1,022 non-Cochrane dental reviews extracted from full text, one record per study, so a study included by several reviews is counted once. Most are randomized trials; etiology and diagnostic reviews also include observational and accuracy studies. Cochrane reviews and reviews with only their headline outcomes do not list their included studies here yet.

ReviewStudies included by Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic…. Show all studies

8 studies

Sort:Most sharedNewestOldest
StudyYearReviewsReview outcomes linkedTrial data
RECIP 1.0 + PSA for response assessment in mCRPC patients treated with 225Ac / 177Lu PSMA combination therapy.
Sheikh 2025 · Sheikh Gabriel T, Delker Astrid, et al. · EJNMMI research
PMID:40038098
202521not extracted yet
225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry.
Rosar 2024 · Rosar Florian, Burgard Caroline, et al. · Clinical nuclear medicine
PMID:38769643
202421not extracted yet
Deescalated 225Ac-PSMA-617 Versus 177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.
Rathke 2024 · Rathke Hendrik, Winter Erik, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine
PMID:38844358
202421not extracted yet
Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients…
Rosar 2021 (Theranostics) · Rosar Florian, Hau Fabian, et al. · Theranostics
PMID:33754047
202121not extracted yet
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.
Rosar 2021 (Pharmaceutics) · Rosar Florian, Krause Jonas, et al. · Pharmaceutics
PMID:34069003
202121not extracted yet
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.
Khreish 2020 · Khreish Fadi, Ebert Niklas, et al. · European journal of nuclear medicine and molecular imaging
PMID:31758224
202021not extracted yet
225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a…
Rosar 2025 · Rosar Florian, Khreish Fadi, et al. · Clinical nuclear medicine
PMID:39787407
202511not extracted yet
Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival…
Burgard 2024 · Burgard Caroline, Khreish Fadi, et al. · Cancers
PMID:39456626
202411not extracted yet